Norditropin

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

The European Medicines Agency has completed an arbitration procedure for Norditropin and associated names. The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on a requested change to the marketing authorisation for these medicines to include a new indication for use in children with Prader-Willi syndrome. The Committee concluded that the change to the marketing authorisation cannot be granted.

Key facts

About this medicine
Approved name
Norditropin
International non-proprietary name (INN) or common name
somatropin
Associated names
  • Norditropin FlexPro
  • Norditropin NordiFlex
  • Norditropin SimpleXx
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-13/1304
Type
Article 13 referrals

This type of referral is triggered for a medicine that has been authorised by mutual recognition or via the decentralised procedure when there is disagreement between Member States on a variation (type II), on the grounds of a potential serious risk to public health.

Key dates and outcomes
CHMP opinion date
15/12/2011
EC decision date
06/03/2012

All documents

  • List item

    Questions and answers on Norditropin and associated names (somatropin, 5 mg, 10 mg and 15 mg/1.5 ml solution for injection) (PDF/57.76 KB)

    Adopted

    First published: 16/12/2011
    Last updated: 19/04/2012
    EMA/CHMP/966954/2011

  • List item

    Norditropin - Article 13 referral - Assessment Report (PDF/96.56 KB)


    First published: 19/04/2012
    Last updated: 19/04/2012
    EMA/171189/2012

  • List item

    Norditropin - Article 13 referral - Annex I (PDF/646.85 KB)


    First published: 19/04/2012
    Last updated: 19/04/2012

  • List item

    Norditropin - Article 13 referral - Annex II (PDF/79.88 KB)


    First published: 19/04/2012
    Last updated: 19/04/2012

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    How useful was this page?

    Add your rating
    Average
    1 rating
    7 ratings